Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdFIrst: BT524 vs Standard of Care in Major Surgery
NCT03444324Phase 3Completed
- Sponsor
- Biotest AG
- Start
- Apr 2018
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, single-blind trial of Fibrinogen human in acquired hypofibrinogenemia (2 arms), sponsored by Biotest AG. Primary endpoint: Intra-operative Blood Loss. Started Apr 2018; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
acquired hypofibrinogenemia
Beyond the preview
Go deeper on NCT03444324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444324.